Loading...
Loading...
BioVaxys Technology Corp.
BioVaxys Technology Corp.. Spoken Alpha tracks BVAXF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks BVAXF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BVAXF.
curl https://api.spokenalpha.com/v1/companies/BVAXF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.33 | $3.29 | -29.3% | +7.8% | +9.8% |
| Q4 FY2026 | $2.54 | $3.40 | -25.3% | +1.7% | +4.1% |
| Q3 FY2026 | $2.48 | $3.37 | -26.3% | +1.9% | +2.2% |
| Q2 FY2026 | $2.59 | $3.32 | -22.0% | -2.2% | -0.9% |
| Q1 FY2025 | $2.51 | $3.40 | -26.3% | -1.5% | -2.9% |
| Q4 FY2025 | $2.37 | $3.42 | -30.6% | +0.3% | +1.2% |
| Q3 FY2025 | $2.48 | $3.42 | -27.6% | +5.7% | +8.6% |
| Q2 FY2025 | $2.64 | $3.62 | -27.1% | +5.4% | +7.6% |
| Q1 FY2024 | $2.50 | $3.59 | -30.4% | -0.5% | +0.2% |
| Q4 FY2024 | $2.97 | $3.64 | -18.4% | -1.4% | -1.7% |